Floatz logo

[177lu]lu-akir001

Poorly Differentiated Thyroid Carcinoma

Karolinska University HospitalradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Poorly Differentiated Thyroid Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
M.D. Anderson Cancer Center
Phase 2CCC
Ipilimumab
M.D. Anderson Cancer Center
Phase 2CCC
Lifileucel
M.D. Anderson Cancer Center
Phase 2CCC
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2CCC
Fludarabine
M.D. Anderson Cancer Center
Phase 2CCC
Gefetinib
National Cancer Institute (NCI)
N/ANR

Same molecule, other indications

[177lu]lu-akir001 is also rated in:

thyroid gland undifferentiated (anaplastic) carcinomaDormant
C
Indicative ·
39 / 100
View asset →
head and neck cancerDormant
C
Indicative ·
39 / 100
View asset →
cervical carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →